NO20060259L - Melanocortinreseptor 4(MC4) agonist og anvendelser derav - Google Patents

Melanocortinreseptor 4(MC4) agonist og anvendelser derav

Info

Publication number
NO20060259L
NO20060259L NO20060259A NO20060259A NO20060259L NO 20060259 L NO20060259 L NO 20060259L NO 20060259 A NO20060259 A NO 20060259A NO 20060259 A NO20060259 A NO 20060259A NO 20060259 L NO20060259 L NO 20060259L
Authority
NO
Norway
Prior art keywords
agonist
melanocortin receptor
peptide agonists
receptor
obesity
Prior art date
Application number
NO20060259A
Other languages
English (en)
Inventor
Hansen Maxwell Hsiung
Mark Louis Heiman
David B Flora
Lianshan Zhang
Jeanne L Hertel
John Philip Mayer
David Lee Smiley
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20060259L publication Critical patent/NO20060259L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det beskrives peptidagonister av MC4-reseptorer. Peptidagonistene er brukbare ved terapi av forstyrrelser som er responsive for aktivering av denne reseptor som obesitet, diabetes mellitus og mannlig og/eller kvinnelig seksuell dysfunksjon.
NO20060259A 2003-06-19 2006-01-18 Melanocortinreseptor 4(MC4) agonist og anvendelser derav NO20060259L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47974003P 2003-06-19 2003-06-19
US55734704P 2004-03-29 2004-03-29
US57073704P 2004-05-13 2004-05-13
US57067604P 2004-05-13 2004-05-13
PCT/US2004/016625 WO2005000339A2 (en) 2003-06-19 2004-06-17 Melanocortin receptor 4(mc4) agonists and their uses

Publications (1)

Publication Number Publication Date
NO20060259L true NO20060259L (no) 2006-03-14

Family

ID=33556652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060259A NO20060259L (no) 2003-06-19 2006-01-18 Melanocortinreseptor 4(MC4) agonist og anvendelser derav

Country Status (17)

Country Link
US (1) US20070105759A1 (no)
EP (1) EP1644023A2 (no)
JP (1) JP2006527773A (no)
KR (1) KR20060014444A (no)
AR (1) AR044824A1 (no)
AU (1) AU2004251616A1 (no)
BR (1) BRPI0410731A (no)
CA (1) CA2530024A1 (no)
CR (1) CR8159A (no)
EA (1) EA200600055A1 (no)
EC (1) ECSP056236A (no)
IL (1) IL171931A0 (no)
MX (1) MXPA05013951A (no)
NO (1) NO20060259L (no)
PE (1) PE20050284A1 (no)
TW (1) TW200514791A (no)
WO (1) WO2005000339A2 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293423A1 (en) 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
ATE350369T1 (de) 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
EP2548568B1 (en) 2005-07-08 2018-01-10 Ipsen Pharma Melanocortin receptor ligands
RU2401841C2 (ru) * 2005-07-08 2010-10-20 Ипсен Фарма С.А.С. Лиганды рецепторов меланокортинов
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN103316345B (zh) 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
EP2238244A1 (en) 2008-01-02 2010-10-13 Danisco A/S Pseudomonas saccharophila g4-amylase variants and uses thereof
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
EP2300036B1 (en) * 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
ES2732077T3 (es) 2011-12-29 2019-11-20 Rhythm Pharmaceuticals Inc Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CN118240012A (zh) * 2013-03-15 2024-06-25 节奏制药公司 肽组合物
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2985734T3 (es) 2015-09-30 2024-11-07 Rhythm Pharmaceuticals Inc Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR101917854B1 (ko) * 2017-08-24 2018-11-12 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물
CN115010793A (zh) * 2022-06-17 2022-09-06 中国农业大学 玫瑰叶畸形病毒外壳蛋白多克隆抗体的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
GB9808229D0 (en) * 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
MXPA01005818A (es) * 1998-12-09 2003-07-21 Eleanor Rooseveltl Inst Composicion y metodo para la regulacion del peso del cuerpo y condiciones asociadas.
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
CA2368431C (en) * 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6659982B2 (en) * 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
DK1315750T3 (da) * 2000-08-30 2007-06-11 Hoffmann La Roche Cykliske peptider med melanocortin-4-receptoragonistaktivitet
CA2453027A1 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
US20070105759A1 (en) 2007-05-10
CR8159A (es) 2006-02-09
CA2530024A1 (en) 2005-01-06
PE20050284A1 (es) 2005-05-20
WO2005000339A8 (en) 2005-04-21
WO2005000339A2 (en) 2005-01-06
ECSP056236A (es) 2006-04-19
JP2006527773A (ja) 2006-12-07
EA200600055A1 (ru) 2006-08-25
MXPA05013951A (es) 2006-02-24
KR20060014444A (ko) 2006-02-15
TW200514791A (en) 2005-05-01
WO2005000339A3 (en) 2005-02-03
AR044824A1 (es) 2005-10-05
BRPI0410731A (pt) 2006-06-20
EP1644023A2 (en) 2006-04-12
IL171931A0 (en) 2006-04-10
AU2004251616A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
NO20060259L (no) Melanocortinreseptor 4(MC4) agonist og anvendelser derav
ATE342057T1 (de) Melanocortinrezeptoragonisten
WO2005030797A3 (en) Melanocortin receptor agonists
WO2008147556A3 (en) Melanocortin receptor ligands modified with hydantoin
WO2001055106A3 (en) Novel melanocortin receptor agonists and antagonists
NO20080052L (no) G-Protein kopplede reseptoragonister
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
WO2002059117A8 (en) Piperazine- and piperidine-derivatives as melanocortin receptor agonists
ECSP045094A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
BR0207658A (pt) Métodos para o tratamento ou a prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, de obesidade, de diabetes melito, de disfunção sexual masculina ou feminina, e de disfunção erétil em um mamìfero que disto necessita, e, composição farmacêutica
WO2002059107A8 (en) Substituted piperidines/piperazines as melanocortin receptor agonists
ATE411021T1 (de) Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
WO2007109135A3 (en) Neuromedin u receptor agonists and uses thereof
WO2003016276A3 (en) 3-substituted oxindole beta-3 agonists
NO20092023L (no) Oligoribonuleotider og anvendelser derav
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
WO2005009950A3 (en) Piperidine derivatives as melanocortin-4 receptor agonists
CL2004000826A1 (es) Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
UA87122C2 (ru) Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения
WO2006023359A3 (en) Selective vpac2 receptor peptide agonists
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
WO2006052626A3 (en) Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders
WO2006121588A3 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
WO2006091505A3 (en) Neuropeptide y receptor agonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application